Dear Editor {#s0005}
===========

We read with great interest the article by Murakawa et al. [@bib1] titled, "*Report of periprocedural oral anticoagulants in catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF).*" The authors concluded that the choice of a novel oral anticoagulant (NOAC) as a periprocedural anticoagulant did not significantly alter the incidence of serious complications, compared with uninterrupted warfarin. However, is this true?

To answer this question, we performed a thorough search of the literature, which resulted in a significant number of recent studies regarding the periprocedural safety and efficacy of NOACs, especially dabigatran [@bib2], [@bib3], [@bib4], [@bib5]. Calkins et al., in a randomized, multicenter controlled trial of 704 patients, reported that in those undergoing ablation for atrial fibrillation (AF), anticoagulation with uninterrupted dabigatran was associated with fewer bleeding complications than uninterrupted warfarin [@bib2]. The incidence of major bleeding episodes during and up to 8 weeks after ablation was lower with dabigatran than with warfarin [@bib2].

A retrospective study from a prospective AF ablation registry presented similar results regarding dabigatran versus warfarin [@bib3]. Dabigatran resulted in fewer minor bleeding episodes and total adverse events after AF ablation [@bib3].

In addition, a comparative study of periprocedural anticoagulants concluded that more bleeding complications occurred with warfarin than with NOACs [@bib4].

Finally, a recent meta-analysis that included 25 studies and a total of 11,686 patients with AF concurred that there is a lower risk of minor bleeding with NOACs than with warfarin [@bib5].

Uninterrupted anticoagulation with a NOAC is associated with minimal bleeding and thromboembolic events [@bib4]. Patients are increasingly being treated with NOACs. Therefore, the choice of NOAC as a periprocedural anticoagulant for AF ablation with minimum interruption of the patient\'s dosing schedule is a feasible alternative therapeutic strategy, which has been proven to be safe and effective.
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